Brief: Actinium Pharmaceuticals Announces Publication Of Results From The Phase 3 Sierra Trial Of Iomab-B
20/09/2024 13:22
Sept 20 (Reuters) - Actinium Pharmaceuticals Inc
ATNM.A :
* ACTINIUM PHARMACEUTICALS ANNOUNCES PUBLICATION OF RESULTS
FROM
THE PHASE 3 SIERRA TRIAL OF IOMAB-B IN THE JOURNAL OF CLINICAL
ONCOLOGY
* ACTINIUM PHARMACEUTICALS INC - IOMAB-B WELL TOLERATED IN
OLDER
RELAPSED/REFRACTORY AML PATIENTS
Source text for Eikon: ID:nPn1HH8zha
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities